Atlantic Pharmaceuticals Relocates Principal Executive Offices from North Carolina to New York.NEW YORK--(BW HealthWire)--Nov. 8, 1999-- Atlantic Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on SmallCap: ATLC ATLC Arbitrary Transmission Line Calculator ATLC Atomic Trades and Labor Council ATLC Air Transport Label Catalog ATLC Advanced Technology Licensing Company ) today announced that it has closed its Raleigh, North Carolina For other uses of this name, see Raleigh. Raleigh (IPA: /ˈrɑli/, ral-ee) is the capital of the State of North Carolina and the county seat of Wake County. office and relocated its principal office to: 150 Broadway Avenue, Suite 1110 New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York 10038 Telephone: 212/227-4714 Facsimile: 212/732-9453 This move will allow Atlantic to avoid unnecessary general and administrative expenses associated with its North Carolina office, and places its principal office close to Atlantic's management, which is New York-based. Atlantic Pharmaceuticals, Inc. Atlantic is engaged in the development of biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. and pharmaceutical products and related technologies. Atlantic's strategy is to identify nascent medical products and technologies that have the potential to address unmet market needs. Atlantic currently has rights to three technologies in the fields of ophthalmic, oncology and infectious disease, and pain and inflammation. Safe Harbor Statement Cautionary statement under the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This press release contains certain forward-looking statements that relate to future scientific, business and financial performance. These statements are only predictions and are subject to a number of risks and uncertainties that may cause the actual events or results to differ from those discussed or implied in these statements. These risks and uncertainties include competition from other manufacturers of cataract-extraction technologies, the unavailability of any necessary intellectual property rights possessed by third parties, and certain of those risks described in Atlantic's most recent report on Form 10-KSB filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion